Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ansgar Brock is active.

Publication


Featured researches published by Ansgar Brock.


Proceedings of the National Academy of Sciences of the United States of America | 2003

Addition of the keto functional group to the genetic code of Escherichia coli

Lei Wang; Zhiwen Zhang; Ansgar Brock; Peter G. Schultz

Although the keto group is the most versatile of the functional groups in organic chemistry, it is absent in the genetically encoded amino acids. To overcome this natural limitation on protein biosynthesis, we have evolved an orthogonal tRNA-synthetase pair that makes possible the efficient incorporation of a keto amino acid, p-acetyl-l-phenylalanine, into proteins in E. coli with high translational fidelity in response to the amber nonsense codon. To demonstrate the utility of this keto amino acid, we have used it to modify a protein selectively with a small molecule fluorophore and biotin derivative. This additional genetically encoded amino acid should greatly expand our ability to manipulate protein structure and function both in vitro and in living cells.


Proceedings of the National Academy of Sciences of the United States of America | 2003

Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry

Arthur R. Salomon; Scott B. Ficarro; Laurence M. Brill; Achim Brinker; Qui T. Phung; Christer Ericson; Karsten Sauer; Ansgar Brock; D. Horn; Peter G. Schultz; Eric C. Peters

The reversible phosphorylation of tyrosine residues is an important mechanism for modulating biological processes such as cellular signaling, differentiation, and growth, and if deregulated, can result in various types of cancer. Therefore, an understanding of these dynamic cellular processes at the molecular level requires the ability to assess changes in the sites of tyrosine phosphorylation across numerous proteins simultaneously as well as over time. Here we describe a sensitive approach based on multidimensional liquid chromatography/mass spectrometry that enables the rapid identification of numerous sites of tyrosine phosphorylation on a number of different proteins from human whole cell lysates. We used this methodology to follow changes in tyrosine phosphorylation patterns that occur over time during either the activation of human T cells or the inhibition of the oncogenic BCR-ABL fusion product in chronic myelogenous leukemia cells in response to treatment with STI571 (Gleevec). Together, these experiments rapidly identified 64 unique sites of tyrosine phosphorylation on 32 different proteins. Half of these sites have been documented in the literature, validating the merits of our approach, whereas motif analysis suggests that a number of the undocumented sites are also potentially involved in biological pathways. This methodology should enable the rapid generation of new insights into signaling pathways as they occur in states of health and disease.


Journal of the American Chemical Society | 2008

In vivo incorporation of unnatural amino acids to probe structure, dynamics and ligand binding in a large protein by Nuclear Magnetic Resonance spectroscopy

Susan E. Cellitti; David H. Jones; Leanna Lagpacan; Xueshi Hao; Qiong Zhang; Huiyong Hu; Scott M. Brittain; Achim Brinker; Jeremy S. Caldwell; Badry Bursulaya; Glen Spraggon; Ansgar Brock; Youngha Ryu; Tetsuo Uno; Peter G. Schultz; Bernhard H. Geierstanger

In vivo incorporation of isotopically labeled unnatural amino acids into large proteins drastically reduces the complexity of nuclear magnetic resonance (NMR) spectra. Incorporation is accomplished by coexpressing an orthogonal tRNA/aminoacyl-tRNA synthetase pair specific for the unnatural amino acid added to the media and the protein of interest with a TAG amber codon at the desired incorporation site. To demonstrate the utility of this approach for NMR studies, 2-amino-3-(4-(trifluoromethoxy)phenyl)propanoic acid (OCF 3Phe), (13)C/(15)N-labeled p-methoxyphenylalanine (OMePhe), and (15)N-labeled o-nitrobenzyl-tyrosine (oNBTyr) were incorporated individually into 11 positions around the active site of the 33 kDa thioesterase domain of human fatty acid synthase (FAS-TE). In the process, a novel tRNA synthetase was evolved for OCF 3Phe. Incorporation efficiencies and FAS-TE yields were improved by including an inducible copy of the respective aminoacyl-tRNA synthetase gene on each incorporation plasmid. Using only between 8 and 25 mg of unnatural amino acid, typically 2 mg of FAS-TE, sufficient for one 0.1 mM NMR sample, were produced from 50 mL of Escherichia coli culture grown in rich media. Singly labeled protein samples were then used to study the binding of a tool compound. Chemical shift changes in (1)H-(15)N HSQC, (1)H-(13)C HSQC, and (19)F NMR spectra of the different single site mutants consistently identified the binding site and the effect of ligand binding on conformational exchange of some of the residues. OMePhe or OCF 3Phe mutants of an active site tyrosine inhibited binding; incorporating (15)N-Tyr at this site through UV-cleavage of the nitrobenzyl-photocage from oNBTyr re-established binding. These data suggest not only robust methods for using unnatural amino acids to study large proteins by NMR but also establish a new avenue for the site-specific labeling of proteins at individual residues without altering the protein sequence, a feat that can currently not be accomplished with any other method.


Nature Biotechnology | 2004

The site-specific incorporation of p-iodo-L-phenylalanine into proteins for structure determination

Jianming Xie; Lei Wang; Ning Wu; Ansgar Brock; Glen Spraggon; Peter G. Schultz

A recently developed method makes it possible to genetically encode unnatural amino acids with diverse physical, chemical or biological properties in Escherichia coli and yeast. We now show that this technology can be used to efficiently and site-specifically incorporate p-iodo-L-phenylalanine (iodoPhe) into proteins in response to an amber TAG codon. The selective introduction of the anomalously scattering iodine atom into proteins should facilitate single-wavelength anomalous dispersion experiments on in-house X-ray sources. To illustrate this, we generated a Phe153 → iodoPhe mutant of bacteriophage T4 lysozyme and determined its crystal structure using considerably less data than are needed for the equivalent experiment with cysteine and methionine. The iodoPhe residue, although present in the hydrophobic core of the protein, did not perturb the protein structure in any meaningful way. The ability to selectively introduce this and other heavy atom–containing amino acids into proteins should facilitate the structural study of proteins.


Nature | 2016

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Shilpi Khare; Advait Nagle; Agnes Biggart; Yin H. Lai; Fang Liang; Lauren C. Davis; S. Whitney Barnes; Casey J. N. Mathison; Elmarie Myburgh; Mu-Yun Gao; J. Robert Gillespie; Xianzhong Liu; Jocelyn L. Tan; Monique Stinson; Ianne Rivera; Jaime Ballard; Vince Yeh; Todd Groessl; Hazel X. Y. Koh; John D. Venable; Badry Bursulaya; Michael B. Shapiro; Pranab Mishra; Glen Spraggon; Ansgar Brock; Jeremy C. Mottram; Frederick S. Buckner; Srinivasa P. S. Rao; Ben G. Wen; John R. Walker

Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually. The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., respectively. These parasites have similar biology and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target. However, no such molecular targets or broad spectrum drugs have been identified to date. Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection. GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice. Our data provide genetic and chemical validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197

Enrico Malito; Badry Bursulaya; Connie Chen; Paola Lo Surdo; Monica Picchianti; Enrico Balducci; Marco Biancucci; Ansgar Brock; Francesco Berti; Matthew J. Bottomley; Mikkel Nissum; Paolo Costantino; Rino Rappuoli; Glen Spraggon

CRM197 is an enzymatically inactive and nontoxic form of diphtheria toxin that contains a single amino acid substitution (G52E). Being naturally nontoxic, CRM197 is an ideal carrier protein for conjugate vaccines against encapsulated bacteria and is currently used to vaccinate children globally against Haemophilus influenzae, pneumococcus, and meningococcus. To understand the molecular basis for lack of toxicity in CRM197, we determined the crystal structures of the full-length nucleotide-free CRM197 and of CRM197 in complex with the NAD hydrolysis product nicotinamide (NCA), both at 2.0-Å resolution. The structures show for the first time that the overall fold of CRM197 and DT are nearly identical and that the striking functional difference between the two proteins can be explained by a flexible active-site loop that covers the NAD binding pocket. We present the molecular basis for the increased flexibility of the active-site loop in CRM197 as unveiled by molecular dynamics simulations. These structural insights, combined with surface plasmon resonance, NAD hydrolysis, and differential scanning fluorimetry data, contribute to a comprehensive characterization of the vaccine carrier protein, CRM197.


Review of Scientific Instruments | 2000

Characterization of a Hadamard transform time-of-flight mass spectrometer

Ansgar Brock; Nestor Rodriguez; Richard N. Zare

A pseudorandom time-of-flight method (also called the cross-correlation method) has been used to perform time-of-flight mass spectrometry with a duty cycle of 50%. Modulation of an ion beam is accomplished by deflecting the ion beam with an interleaved comb of oppositely charged elements. Maximum-length pseudorandom sequences based on Hadamard-type difference sets are produced by feedback shift register circuitry and used for ion beam modulation. The inverse transformation of the recorded signal is carried out speedily with the help of the fast Hadamard transform, which allows real-time monitoring of the mass spectrum. The components of the instrument are described, and its performance is characterized. Trajectory simulations are found to be in good agreement with experimental findings, which aids in understanding the modulation dynamics. It is found that the wire comb modulator can be modeled as a set of ideal deflection plates of length 0.875 l, where l is the spacing between oppositely charged wires.


Biochemistry | 2009

Expanding the Genetic Repertoire of the Methylotrophic Yeast Pichia pastoris

Travis S. Young; Insha Ahmad; Ansgar Brock; Peter G. Schultz

To increase the utility of protein mutagenesis with unnatural amino acids, a recombinant expression system in the methylotrophic yeast Pichia pastoris was developed. Aminoacyl-tRNA synthetase/suppressor tRNA (aaRS/tRNA(CUA)) pairs previously evolved in Saccharomyces cerevisiae to be specific for unnatural amino acids were inserted between eukaryotic transcriptional control elements and stably incorporated into the P. pastoris genome. Both the Escherichia coli tyrosyl- and leucyl-RS/tRNA(CUA) pairs were shown to be orthogonal in P. pastoris and used to incorporate eight unnatural amino acids in response to an amber codon with high yields and fidelities. In one example, we show that a recombinant human serum albumin mutant containing a keto amino acid (p-acetylphenylalanine) can be efficiently expressed in this system and selectively conjugated via oxime ligation to a therapeutic peptide mimetic containing an permittivity-(2-(aminooxy)acetyl)-L-lysine residue. Moreover, unnatural amino acid expression in the methylotrophic host was systematically optimized by modulation of aaRS levels to express mutant human serum albumin in excess of 150 mg/L in shake flasks, more than an order of magnitude better than that reported in S. cerevisiae. This methodology should allow the production of high yields of complex proteins containing unnatural amino acids whose expression is not practical in existing systems.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Site-specific protein modifications through pyrroline-carboxy-lysine residues

Weijia Ou; Tetsuo Uno; Hsien-Po Chiu; Jan Grunewald; Susan E. Cellitti; Tiffany Crossgrove; Xueshi Hao; Qian Fan; Lisa Quinn; Paula Patterson; Linda Okach; David H. Jones; Scott A. Lesley; Ansgar Brock; Bernhard H. Geierstanger

Pyrroline-carboxy-lysine (Pcl) is a demethylated form of pyrrolysine that is generated by the pyrrolysine biosynthetic enzymes when the growth media is supplemented with D-ornithine. Pcl is readily incorporated by the unmodified pyrrolysyl-tRNA/tRNA synthetase pair into proteins expressed in Escherichia coli and in mammalian cells. Here, we describe a broadly applicable conjugation chemistry that is specific for Pcl and orthogonal to all other reactive groups on proteins. The reaction of Pcl with 2-amino-benzaldehyde or 2-amino-acetophenone reagents proceeds to near completion at neutral pH with high efficiency. We illustrate the versatility of the chemistry by conjugating Pcl proteins with poly(ethylene glycol)s, peptides, oligosaccharides, oligonucleotides, fluorescence, and biotin labels and other small molecules. Because Pcl is genetically encoded by TAG codons, this conjugation chemistry enables enhancements of the pharmacology and functionality of proteins through site-specific conjugation.


Chemistry & Biology | 2009

Photocleavage of the Polypeptide Backbone by 2-Nitrophenylalanine

Francis B. Peters; Ansgar Brock; Jiangyun Wang; Peter G. Schultz

Photocleavage of the polypeptide backbone is potentially a powerful and general method to activate or deactivate functional peptides and proteins with high spatial and temporal resolution. Here we show that 2-nitrophenylalanine is able to photochemically cleave the polypeptide backbone by an unusual cinnoline-forming reaction. This unnatural amino acid was genetically encoded in E. coli, and protein containing 2-nitrophenylalanine was expressed and site-specifically photocleaved.

Collaboration


Dive into the Ansgar Brock's collaboration.

Top Co-Authors

Avatar

Eric C. Peters

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Peter G. Schultz

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Bernhard H. Geierstanger

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Tetsuo Uno

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Glen Spraggon

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Badry Bursulaya

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Christer Ericson

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

John D. Venable

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Researchain Logo
Decentralizing Knowledge